CN113073116A - 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用 - Google Patents

一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用 Download PDF

Info

Publication number
CN113073116A
CN113073116A CN202110362266.0A CN202110362266A CN113073116A CN 113073116 A CN113073116 A CN 113073116A CN 202110362266 A CN202110362266 A CN 202110362266A CN 113073116 A CN113073116 A CN 113073116A
Authority
CN
China
Prior art keywords
leu
ser
ile
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110362266.0A
Other languages
English (en)
Other versions
CN113073116B (zh
Inventor
刘金华
孙洪磊
孙浩然
李涵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN202110362266.0A priority Critical patent/CN113073116B/zh
Publication of CN113073116A publication Critical patent/CN113073116A/zh
Application granted granted Critical
Publication of CN113073116B publication Critical patent/CN113073116B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供一种表达冠状病毒Spike蛋白的重组副流感病毒5型载体,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述基因组包含冠状病毒Spike蛋白突变体的编码序列;所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列,且冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点。结果表明,免疫重组病毒rPIV5‑SH‑Spike组小鼠体内产生抗体针对新冠病毒Spike蛋白的特异性抗体,而rPIV5对照组小鼠未能检测到针对新冠病毒Spike蛋白的特异性抗体。表明rPIV5‑SH‑Spike重组病毒免疫小鼠能够刺激小鼠产生针对Spike蛋白的特异性抗体。

Description

一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用
技术领域
本发明涉及生物技术领域,具体涉及一种表达新冠病毒Spike蛋白重组副流感病毒 5型制备和应用。
背景技术
新冠肺炎的临床症状包括发热、干咳、乏力等,患者可出现鼻塞、流涕、咽痛、结膜炎等多种症状,重症患者可出现呼吸困难、低氧血症,严重者可发展为急性呼吸窘迫综合征、脓毒症休克等甚至导致死亡。疫苗接种是预防新冠病毒的最有效手段之一,目前各国已有多个研究机构进行新冠疫苗的制备,包括灭活疫苗,重组蛋白疫苗,重组腺病毒疫苗,mRNA疫苗以及病毒载体疫苗等。灭活疫苗可以有效地激发高水平的体液免疫,相对安全,但不能诱导细胞毒T淋巴细胞反应,不能够产生局部免疫反应;重组蛋白疫苗技术成熟,不良反应小,但生产速度较慢;重组腺病毒疫苗虽然免疫效果好,但可能会存在一定的不良反应,且人体内可能含有针对腺病毒载体的抗体,会影响疫苗效果;mRNA疫苗相对效果好,但存储运输条件相对较为苛刻,成本较高。
病毒载体疫苗具有多种优势,由于是活病毒载体,可在免疫机体内进行复制,诱导较强的免疫反应;可通过自然感染,如滴鼻、喷雾等方式进行免疫;可产生体液免疫与细胞免疫,除了激发全身免疫反应外,还可激发局部免疫反应,如在呼吸道中产生sIgA 抗体,发挥较强的免疫保护效果。目前,在新冠疫苗的研发过程中,已有多种病毒载体疫苗在研发过程中,并在动物模型中具有良好的免疫保护效果,如黄热病毒、痘病毒、新城疫病毒、水疱口炎病毒等。副流感病毒5型(PIV5)作为预防犬窝咳的疫苗在犬中应用已有数十年的历史,而且未被证实可引起任何其他动物包括人致病。
发明内容
本发明提供一种表达冠状病毒Spike蛋白的重组副流感病毒5型载体,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述基因组包含冠状病毒Spike蛋白突变体的编码序列;所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列,且冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点 (RRAR)。
可选的,所述冠状病毒为2019-nCoV。
可选的,所述副流感病毒5型基因组为:用序列甲替换一种副流感病毒5型基因组的小疏水蛋白基因核苷酸序列,所得;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示核苷酸序列第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位核苷酸由A突变为G,且第2044位至2055位替换为 GCA,得到的DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点(RRAR),所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点(RRAR),所述冠状病毒Spike 蛋白突变体的编码序列不含有副黏病毒转录终止序列。
冠状病毒Spike蛋白突变体的氨基酸序列为SEQ ID NO:2的第682位-685位的氨基酸Arg Arg Ala Arg(RRAR)替换为Ala(A),其他序列保持不变,所得序列。
一种在细胞中表达冠状病毒Spike蛋白的方法,该方法包括使该细胞与上述的表达冠状病毒Spike蛋白的重组副流感病毒5型载体相接触。
一种表达冠状病毒Spike蛋白的重组副流感病毒5型载体的制备方法,包括如下步骤:
1)将副流感病毒5型全基因组反转录得到的cDNA插入克隆载体中,得到重组质粒pPIV5;
2)用序列甲替换步骤1)中重组质粒pPIV5中副流感病毒5型的小疏水蛋白基因核苷酸序列;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示核苷酸序列第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位核苷酸由A突变为G,且第2044位至2055位替换为GCA,得到的DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点(RRAR),所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点RRAR,所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列。
可选的,步骤1)中所述克隆载体为带有T7 RNA聚合酶启动子序列、带有丁肝核酶序列、T7 RNA聚合酶转录终止序列的克隆载体。
一种新型冠状病毒(2019-nCoV)疫苗的制备方法,所述疫苗的制备方法包括如下步骤:将上述表达冠状病毒Spike蛋白的重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L共转染宿主细胞;所述表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L是将副流感病毒5 型的NP、P和L蛋白的编码基因分别插入哺乳动物表达载体中,得到辅助重组质粒— NP、辅助重组质粒—P和辅助重组质粒—L。
可选的,NP蛋白的氨基酸序列如SEQ ID NO:3所示;P蛋白的氨基酸序列如SEQ IDNO:4所示;L蛋白的氨基酸序列如SEQ ID NO:5所示。
可选的,所述宿主细胞为BSR-T7细胞,MDBK细胞,Vero细胞或BHK-21细胞。
上述方法制备得到的疫苗。
上述重组副流感病毒5型载体或上述方法制备的重组副流感病毒5型载体在如下任一一种中的应用:
(1)制备提高动物体内针对冠状病毒2019-nCoV Spike蛋白抗体水平的产品中的应用;
(2)制备预防或辅助预防冠状病毒2019-nCoV引起的疾病产品中的应用。
步骤3)中哺乳动物表达载体为pcDNA3.1(+)。
本发明技术方案,具有如下优点:
结果表明,免疫重组病毒rPIV5-SH-Spike组小鼠体内产生抗体针对新冠病毒Spike 蛋白的特异性抗体,而rPIV5对照组小鼠未能检测到针对新冠病毒Spike蛋白的特异性抗体。表明rPIV5-SH-Spike重组病毒免疫小鼠能够刺激小鼠产生针对Spike蛋白的特异性抗体。
首免后6周,每只小鼠滴鼻感染新冠病毒SARS-CoV-2,接种剂量104,之后每天观察小鼠的临床症状,并在攻毒后第3天,每组各剖检5只小鼠,采集小鼠肺脏,研磨组织,取上清液提取RNA后利用实时荧光定量PCR方法检测新冠病毒在小鼠脏器中的复制水平。试验结果见图5,结果表明,免疫rPIV5-SH-Spike的小鼠肺脏病毒滴度显著低于对照组PIV5-WT组的肺脏病毒滴度,具有良好的免疫保护效果。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是实施例1利用RT-PCR对rPIV5-SH-Spike病毒基因组中Spike基因进行鉴定;
图2是实施例1利用间接免疫荧光对rPIV5-SH-Spike重组病毒感染细胞Spike 蛋白表达情况进行鉴定;
图3是实施例1利用Western blot对rPIV-SH-Spike重组病毒感染细胞Spike蛋白表达情况进行鉴定
图4是实施例1小鼠免疫后血清中针对SARS-CoV-2Spike蛋白ELISA抗体水平;
图5是实施例1中利用RT-qPCR检测新冠病毒在感染免疫后小鼠肺脏中N、ORF 与S基因的水平。
图6是实施例1中重组质粒pPIV5的图谱。
具体实施方式
下述pBlueScript SK II(+)-1载体,公众可从申请人处获得,该生物材料只为重复本发明的相关实验所用,不可作为其它用途使用。
实施例1
1.重组副流感病毒5型的制备
1.1PIV5反向遗传操作系统质粒的构建
1、合成载体病毒PIV5为本实验室在山东省某猪场健康猪体内分离得到的病毒株(命名为CHNSD-011),利用Roche RNA提取试剂盒对该毒株提取RNA并利用PrimeScriptTM II1st Strand cDNA Synthesis Kit反转录,获得毒株的cDNA。将PIV5全长15246nt(见 SEQID NO:6)分为A-C共3个约5-5.5kb大小片段,A片段为PIV5全长(5’-3’)的第1bp-5030bp,B片段为PIV5全长(5’-3’)的第5016bp-9906bp,C片段为PIV5全长(5’-3’)的第9892-15246bp。利用引物分别进行PCR扩增,将DNA片段回收后的A、 B和C分别插入pEasy-BluntZero载体,经测序确认序列无误后保留,三片段的质粒分别命名为pZero-A、pZero-B与pZero-C。
2、改造pBlueScript SK II(+)(优宝生物,货号为VT1328),改造后载体5’端带有T7 RNA聚合酶启动子序列,3’端带有丁肝核酶序列和T7 RNA聚合酶转录终止序列的pBlueScript SK II(+),其他序列不变,改造后的载体命名为pBlueScript SK II(+)-1,将步骤1中得到的三个质粒,利用引物进行PCR扩增,获得分为三段(A、B、 C)的PIV5全基因组,将PIV5全基因组与pBlueScript SK II(+)-1进行同源重组连接,得到重组质粒pPIV5,重组质粒pPIV5图谱见图6(即在pBlueScript SK II(+)-1的中插入序列SEQ ID NO:6),测序验证正确并保留。
以pPIV5为模板,以表2中的SphI-F(SEQ ID NO:7)与SphI-R(SEQ ID NO: 8)引物扩增片段SphI,并在片段3’端引入PmeI酶切位点;以BbvCI-F(SEQ ID NO: 9)与BbvCI-R(SEQ ID NO:10)引物扩增片段BbvCI,并在引物5’端引入PmeI酶切位点,将两片段回收备用。
表2
Figure RE-GDA0003039279420000051
利用SphI-F与BbvCI-R引物扩增片段SphI和BbvCI,扩增得到的目的片段为将SphI和BbvCI片段中的小疏水蛋白基因替换为PmeI识别序列,命名为△SH(此步骤的目的为引入PmeI识别序列,删除小疏水蛋白基因)。
利用SphI与BbvCI双酶切pPIV5载体,回收后与片段△SH进行同源重组,获得携带有PmeI酶切位点的载体vPIV5-PmeI。vPIV5-PmeI载体为将重组质粒pPIV5中的小疏水蛋白基因(sh,为SEQ ID NO:6的第6303-6437位)替换为PmeI识别序列的片段,其他序列保持不变,得到的载体。
3、利用基因NP、P和L特异性引物对(NP的引物对为NP-F、NP-R;P的引物对为P-F、P-R;L的引物对为L-F、L-R),步骤2中得到的重组质粒pPIV5进行扩增,获得NP的基因序列为基因组全长152位到1681位(NP蛋白的氨基酸序列如SEQ ID NO: 3所示),P的基因序列为基因组全长1850位到3026位(P蛋白的氨基酸序列如SEQ ID NO:4所示),L的基因序列为基因组全长序列8414位到15181位(L蛋白的氨基酸序列如SEQ ID NO:5所示)。将NP的基因序列插入购自Invitrogen公司的pcDNA3.1(+) (货号:V790-20)的HindIII位点,获得可在真核细胞中表达病毒蛋白NP的重组质粒 pcDNA-NP;将P的基因序列插入pcDNA3.1(+)的HindIII位点,获得可在真核细胞中表达病毒蛋白P的重组质粒pcDNA-P;将L的基因序列插入pcDNA3.1(+)的HindIII位点,获得可在真核细胞中表达病毒蛋白L的重组质粒pcDNA-L。
1.2重组病毒rPIV5感染性克隆的获得
1、将纯化提取所得步骤1.1中的pPIV5、pcDNA-NP、pcDNA-P与pcDNA-L 共转染稳定表达T7 RNA聚合酶的BSR T7/5细胞。
2、完成步骤1后72h,将转染后的BSR T7/5细胞与上清置于-80℃冻融后,接种MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
3、完成步骤2后72h,吸取细胞上清液,接种新的MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
4、完成步骤3后72h,重复步骤3一次,取细胞上清接种至新的MDBK细胞。 72h后,吸取MDBK细胞上清液进行血凝检测,能够产生血凝现象的上清液即为拯救成功的重组rPIV5,进行后续的检测与鉴定工作。
2.重组质粒pPIV5-SH-Spike的构建
1、利用Primestar HS高保真酶对新冠病毒参考序列(NCBI序列号:NC_045512.2)Spike蛋白表达质粒pcDNA-Spike(受赠于博迈德公司,Spike Protein of SARS-CoV-2Activates Macrophages and Contributes to Induction of Acute LungInflammations in Mice. https://doi.org/10.1101/2020.12.07.414706)进行扩增,并利用融合PCR的方法将Spike 编码序列中的部分位点进行突变,突变副黏病毒转录终止序列。具体操作为,利用 Spike-mut-1F、Spike-mut-1R,Spike-mut-2F、Spike-mut-2R,Spike-mut-3F、Spike-mut-3R, Spike-mut-4F、Spike-mut-4R(表1)四对引物分别对pcDNA-Spike质粒进行扩增,分别获得四个片段1,2,3,4,上述对Spike基因进行PCR扩增,通过上游引物Spike-mut-1F 在Spike基因编码区5’端添加同源臂与Kozak序列,通过下游引物Spike-mut-4R添加同源臂,电泳鉴定无误后对四个片段进行回收。
表1
Figure RE-GDA0003039279420000061
Figure RE-GDA0003039279420000071
2、利用引物Spike-mut-1F、Spike-mut-2R以片段1和2的混合物为模板进行扩增,获得片段1和片段2融合产物12(此步骤的目的是突变Spike基因序列第927位核苷酸 A为G);利用引物Spike-mut-3F、Spike-mut-4R以片段3和4的混合物为模板进行扩增,获得片段3,4融合产物34(此步骤的目的是突变Spike基因序列第3216位核苷酸 A为G)。将两融合片段产物电泳鉴定无误后回收DNA产物备用。
3、利用In-Fusion无缝克隆试剂盒将Spike片段12、片段34及pBlueScript SK II(+)-1进行同源重组,构建Spike突变体质粒,片段12与34进行融合时将Spike基因序列第2106位A核苷酸突变为G,构建中间载体pBK-Spike,测序无误后提取质粒,保留备用。中间载体pBK-Spike为在pBlueScript SK II(+)-1中插入Spike基因的突变序列,Spike基因的突变序列为Spike基因的第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位A核苷酸突变为G。
4、利用Spike-mut-1F与Spike-Furin-del-R、Spike-Furin-del-F与Spike-mut-4R分别对pBK-Spike载体进行PCR扩增,得到Spike-mut-1和Spike-mut-2DNA分子,电泳确认DNA分子大小后进行回收备用(此步骤的目的是突变Spike蛋白的氨基酸序列上的Furin蛋白酶裂解位点RRAR氨基酸为A)。
5、以1.1中的片段pPIV5-PmeI为载体,与步骤4中的Spike-mut-1与Spike-mut-2片段进行同源重组连接,得到重组质粒pPIV5-SH-Spike,测序无误后保留备用。 pPIV5-SH-Spike为在vPIV5-PmeI载体PmeI识别位点插入DNA分子,该DNA分子为 spike基因的突变序列,该spike基因的突变序列为Spike基因(SEQ ID NO:1)的第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位核苷酸由A突变为 G,且第2044位至2055位的核苷酸替换为GCA。
3.表达新冠病毒Spike蛋白的重组副流感病毒5型的拯救
1、将纯化提取所得以上步骤中的pPIV5-SH-Spike、pcDNA-NP、pcDNA-P与 pcDNA-L四质粒共转染表达T7 RNA聚合酶的BSR T7/5细胞。
2、完成步骤1后72h,将BSR T7/5细胞与上清置于-80℃冻融后,接种MDBK细胞,4h后更换为含有2%FBS的DMEM培养基。
3、完成步骤2后72h,吸取细胞上清液,接种新的MDBK细胞,4h后更换为含有 2%FBS的DMEM培养基。
4、完成步骤3后72h,重复步骤3一次,接种至新的MDBK细胞。72h后,吸取 MDBK细胞上清液进行血凝检测,能够产生血凝的上清液即为拯救成功的重组 rPIV5-SH-Spike,进行后续的检测与鉴定工作。
4.重组病毒rPIV5-SH-Spike的鉴定
一、基因鉴定
提取重组病毒rPIV5-SH-Spike基因组RNA,进行反转录获得cDNA后,利用引物 SH-JF与SH-JR对包含有插入Spike基因的病毒基因组区域进行PCR扩增,获得PCR 扩增产物。
试验结果见图1,PCR扩增产物片段为4133bp,片段大小符合预期,经Sanger测序后确认,Spike基因已完全插入PIV5基因组中。
二、间接免疫荧光鉴定
1、取12孔细胞培养板,加入1mL含有MDBK细胞的含10%FBS的DMEM 培养液(约2×105个MDBK细胞),于37℃、5%CO2培养过夜,至MDBK细胞约长至90%密度。
2、完成步骤1后,利用pH为7.2、0.01M的PBS缓冲液清洗细胞两次,弃去液体,更换为含2%FBS的DMEM培养基1mL,并接种重组病毒rPIV5-SH-Spike 104 TCID50,继续培养48h。
3、完成步骤2后,弃去细胞孔中上清,利用pH7.2、0.01M的PBS缓冲液洗涤2次,之后每孔加入1mL预冷的固定液(乙醇与丙酮按照3:2体积比混合配制而成),静置20min,进行细胞固定与透化。
4、完成步骤3后,弃去孔中液体,每孔利用1mL PBS缓冲液洗涤3次,每次 5min;之后每孔加入500μL鼠抗PIV5或兔抗SARS-CoV-2病毒Spike蛋白多克隆抗体稀释液(由1体积份鼠/兔抗体和199体积份pH7.2、0.01M的PBS缓冲液混合而成,鼠抗PIV5稀释液购自武汉华美生物,货号:CSB-MA000160,兔抗SARS-CoV Spike 蛋白抗体,购自义翘神州,货号为40150-T62-COV2)),4℃过夜孵育8h。
5、完成步骤4后,弃去液体,利用PBS缓冲液1mL洗涤3次,每次5min;而后加入TRITC基团标记的羊抗鼠二抗(1:400体积比利用PBS缓冲液稀释)进行抗原抗体结合染色,37℃避光孵育1h。羊抗鼠二抗购自BioVision公司,货号:6921-100
6、完成步骤5后,弃去孔内液体,利用PBS缓冲液1mL洗涤3次,每次5min;而后加入FITC基团标记的羊抗兔二抗(1:200体积比利用PBS缓冲液稀释),进行抗原抗体结合染色,37℃避光孵育1h。羊抗兔二抗购自碧云天生物技术有限公司,货号: A0562。
7、完成步骤6后,弃去孔内液体,利用PBST缓冲液1mL洗涤3次,每次5min,最后一次保留孔内PBST缓冲液不弃去,置于倒置荧光显微镜下观察。将重组病毒 rPIV5-SH-Spike替换为重组野生病毒rPIV5作为对照。
试验结果见图2。结果表明,重组病毒rPIV5-SH-Spike感染MDBK细胞48h后,可在细胞中检测到表达的PIV5 P蛋白(红色)与新冠病毒Spike蛋白(绿色);而重组野生病毒rPIV5感染细胞后仅能检测到PIV5 P蛋白(红色),不能检测到新冠病毒Spike 蛋白(绿色),表明重组病毒rPIV5-SH-Spike可在感染后细胞中表达Spike蛋白。
三、Western blot鉴定
1、取6孔细胞培养板,加入2mL含有MDBK细胞的细胞培养液(约4×105个 CEF细胞/孔),37℃、5%CO2培养过夜,直至MDBK细胞生长成单层至约90%密度。
2、完成步骤1后,利用2mL PBS洗涤细胞三次,接种重组病毒rPIV5-SH-Spike 或rPIV5(接种剂量为104TCID50)并更换为含2%FBS的DMEM培养液,37℃、5%CO2培养48h。
3、取完成步骤2的细胞,PBS洗涤三次后,加入PBS后利用细胞刮刀小新刮下细胞,离心,弃去上清收集细胞。
4、完成步骤3后,取所述细胞,利用IP裂解液进行裂解,得到细胞裂解液,10000g离心10min后小心吸取上清,加入Western Protein Loading Buffer,100℃变性10min 后冷却至室温。
5、完成步骤4后,将所述细胞裂解液进行SDS-PAGE和Western blot,采用兔抗新冠病毒Spike蛋白多克隆抗体(Sino Biological公司,0150-T62-COV2)作为一抗采根过氧化物酶(HRP)标记的羊抗兔抗体(碧云天生物技术有限公司,货号:A0208) 作为二抗检测Spike蛋白;利用PIV5 P蛋白作为内参,鼠抗V5标签单克隆抗体(武汉华美生物技术有限公司,货号:CSB-MA000160)为一抗,HRP标记羊抗鼠抗体(Abcam 公司,货号:ab6789)作为二抗。
实验结果见图3。结果表明,重组病毒rPIV5-SH-Spike感染的MDBK细胞中能够在230KD大小位置检测到Spike蛋白特异性条带,而rPIV5感染的MDBK细胞中未检测到该特异性条带,表明重组病毒rPIV5-SH-Spike感染细胞后可表达新冠病毒Spike 蛋白。
四、重组病毒pPIV5-SH-Spike对新冠病毒SARS-CoV-2的免疫保护效果评价
将20只6周龄BALB/c小鼠随机分成两组,每组10只。实验组鼻腔接种50μL重组病毒rPIV5-SH-Spike,对照组鼻腔接种50μL重组病毒rPIV5,接种剂量均为 106TCID50/只。首次接种后15天,重复上述操作一次。免疫后持续观察每组小鼠的临床症状:包括是否出现食欲不振,被毛凌乱,呼吸困难和活动量减少等行为。
观察发现,rPIV5对照组与rPIV5-SH-Spike免疫组均未出现明显的临床症状,饮食正常,体重保持相对稳定。表明本研究构建的重组rPIV5及表达新冠病毒Spike蛋白的rPIV5-SH-Spike重组病毒对小鼠无副反应或不良反应,安全性良好。
在首次免疫后每间隔7天利用眼眶后静脉丛法采集小鼠血液,每组采集10只,制备血清,利用间接ELISA方法对小鼠体内针对Spike蛋白抗体水平进行检测。间接ELISA 方法的步骤为:
1)包板,用ELISA coating buffer(索莱宝公司,C1055)稀释SARS-2-S(Vazyme,货号:CG202-00)到1μg/mL,每孔加50μL,4℃孵育过夜。
2)移除抗原溶液,用PBS清洗3次。
3)封闭,每孔加100μL封闭液(含5%脱脂乳PBS缓冲液),在37℃孵育至少1 小时。
4)移除封闭液,用PBS洗板3次;
5)用血清孵育,用抗体稀释液(即封闭液)稀释血清到正确的比例,小鼠血清稀释从1:25开始,按照排板要求,孔里加入100μL血清稀释液,在37℃孵育2小时,阴性对照为健康鼠的血清,阳性对照要确保检测出来。
6)移除血清稀释液,用PBST洗板5次。
7)用2抗(HRP-conjugated goat anti-mouse IgG,Abcam公司,货号ab6789)孵育,2抗用抗体稀释缓冲液稀释,anti-mouse igG的稀释比例是1:5000,按照排板要求,孔里加入100μL 2抗稀释液,在37℃孵育1.5小时。
8)移除2抗缓冲液,用PBST洗板5次。
9)每孔加入100μL TMB显色液(Beyotime,P0209),轻微拍打孔板,使其混合均匀,在室温孵育一段时间,当阴性孔有变蓝的趋势时,每孔加入100μL终止液,终止反应。
10)用酶标仪在450nm处记录吸光值。
试验结果详见图4(图4中的“免疫后1、2、3、4周”均指“首免后”),结果表明,免疫重组病毒rPIV5-SH-Spike组小鼠体内产生抗体针对新冠病毒Spike蛋白的特异性抗体,而rPIV5对照组小鼠未能检测到针对新冠病毒Spike蛋白的特异性抗体。表明 rPIV5-SH-Spike重组病毒免疫小鼠能够刺激小鼠产生针对Spike蛋白的特异性抗体。
首免后6周,每只小鼠滴鼻感染新冠病毒SARS-CoV-2,接种剂量104TCID50,之后每天观察小鼠的临床症状,并在攻毒后第3天,每组各剖检5只小鼠,采集小鼠肺脏,研磨组织,取上清液提取RNA后利用实时荧光定量PCR方法检测新冠病毒在小鼠脏器中的复制水平。试验结果见图5,结果表明,免疫rPIV5-SH-Spike的小鼠肺脏病毒滴度显著低于对照组PIV5-WT组的肺脏病毒滴度,具有良好的免疫保护效果。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
序列表
<110> 中国农业大学
<120> 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用
<160> 22
<170> SIPOSequenceListing 1.0
<210> 1
<211> 3822
<212> DNA
<213>人工序列
<400> 1
atgtttgttt ttcttgtttt attgccacta gtctctagtc agtgtgttaa tcttacaacc 60
agaactcaat taccccctgc atacactaat tctttcacac gtggtgttta ttaccctgac 120
aaagttttca gatcctcagt tttacattca actcaggact tgttcttacc tttcttttcc 180
aatgttactt ggttccatgc tatacatgtc tctgggacca atggtactaa gaggtttgat 240
aaccctgtcc taccatttaa tgatggtgtt tattttgctt ccactgagaa gtctaacata 300
ataagaggct ggatttttgg tactacttta gattcgaaga cccagtccct acttattgtt 360
aataacgcta ctaatgttgt tattaaagtc tgtgaatttc aattttgtaa tgatccattt 420
ttgggtgttt attaccacaa aaacaacaaa agttggatgg aaagtgagtt cagagtttat 480
tctagtgcga ataattgcac ttttgaatat gtctctcagc cttttcttat ggaccttgaa 540
ggaaaacagg gtaatttcaa aaatcttagg gaatttgtgt ttaagaatat tgatggttat 600
tttaaaatat attctaagca cacgcctatt aatttagtgc gtgatctccc tcagggtttt 660
tcggctttag aaccattggt agatttgcca ataggtatta acatcactag gtttcaaact 720
ttacttgctt tacatagaag ttatttgact cctggtgatt cttcttcagg ttggacagct 780
ggtgctgcag cttattatgt gggttatctt caacctagga cttttctatt aaaatataat 840
gaaaatggaa ccattacaga tgctgtagac tgtgcacttg accctctctc agaaacaaag 900
tgtacgttga aatccttcac tgtagaaaaa ggaatctatc aaacttctaa ctttagagtc 960
caaccaacag aatctattgt tagatttcct aatattacaa acttgtgccc ttttggtgaa 1020
gtttttaacg ccaccagatt tgcatctgtt tatgcttgga acaggaagag aatcagcaac 1080
tgtgttgctg attattctgt cctatataat tccgcatcat tttccacttt taagtgttat 1140
ggagtgtctc ctactaaatt aaatgatctc tgctttacta atgtctatgc agattcattt 1200
gtaattagag gtgatgaagt cagacaaatc gctccagggc aaactggaaa gattgctgat 1260
tataattata aattaccaga tgattttaca ggctgcgtta tagcttggaa ttctaacaat 1320
cttgattcta aggttggtgg taattataat tacctgtata gattgtttag gaagtctaat 1380
ctcaaacctt ttgagagaga tatttcaact gaaatctatc aggccggtag cacaccttgt 1440
aatggtgttg aaggttttaa ttgttacttt cctttacaat catatggttt ccaacccact 1500
aatggtgttg gttaccaacc atacagagta gtagtacttt cttttgaact tctacatgca 1560
ccagcaactg tttgtggacc taaaaagtct actaatttgg ttaaaaacaa atgtgtcaat 1620
ttcaacttca atggtttaac aggcacaggt gttcttactg agtctaacaa aaagtttctg 1680
cctttccaac aatttggcag agacattgct gacactactg atgctgtccg tgatccacag 1740
acacttgaga ttcttgacat tacaccatgt tcttttggtg gtgtcagtgt tataacacca 1800
ggaacaaata cttctaacca ggttgctgtt ctttatcagg atgttaactg cacagaagtc 1860
cctgttgcta ttcatgcaga tcaacttact cctacttggc gtgtttattc tacaggttct 1920
aatgtttttc aaacacgtgc aggctgttta ataggggctg aacatgtcaa caactcatat 1980
gagtgtgaca tacccattgg tgcaggtata tgcgctagtt atcagactca gactaattct 2040
cctcggcggg cacgtagtgt agctagtcaa tccatcattg cctacactat gtcacttggt 2100
gcagaaaatt cagttgctta ctctaataac tctattgcca tacccacaaa ttttactatt 2160
agtgttacca cagaaattct accagtgtct atgaccaaga catcagtaga ttgtacaatg 2220
tacatttgtg gtgattcaac tgaatgcagc aatcttttgt tgcaatatgg cagtttttgt 2280
acacaattaa accgtgcttt aactggaata gctgttgaac aagacaaaaa cacccaagaa 2340
gtttttgcac aagtcaaaca aatttacaaa acaccaccaa ttaaagattt tggtggtttt 2400
aatttttcac aaatattacc agatccatca aaaccaagca agaggtcatt tattgaagat 2460
ctacttttca acaaagtgac acttgcagat gctggcttca tcaaacaata tggtgattgc 2520
cttggtgata ttgctgctag agacctcatt tgtgcacaaa agtttaacgg ccttactgtt 2580
ttgccacctt tgctcacaga tgaaatgatt gctcaataca cttctgcact gttagcgggt 2640
acaatcactt ctggttggac ctttggtgca ggtgctgcat tacaaatacc atttgctatg 2700
caaatggctt ataggtttaa tggtattgga gttacacaga atgttctcta tgagaaccaa 2760
aaattgattg ccaaccaatt taatagtgct attggcaaaa ttcaagactc actttcttcc 2820
acagcaagtg cacttggaaa acttcaagat gtggtcaacc aaaatgcaca agctttaaac 2880
acgcttgtta aacaacttag ctccaatttt ggtgcaattt caagtgtttt aaatgatatc 2940
ctttcacgtc ttgacaaagt tgaggctgaa gtgcaaattg ataggttgat cacaggcaga 3000
cttcaaagtt tgcagacata tgtgactcaa caattaatta gagctgcaga aatcagagct 3060
tctgctaatc ttgctgctac taaaatgtca gagtgtgtac ttggacaatc aaaaagagtt 3120
gatttttgtg gaaagggcta tcatcttatg tccttccctc agtcagcacc tcatggtgta 3180
gtcttcttgc atgtgactta tgtccctgca caagaaaaga acttcacaac tgctcctgcc 3240
atttgtcatg atggaaaagc acactttcct cgtgaaggtg tctttgtttc aaatggcaca 3300
cactggtttg taacacaaag gaatttttat gaaccacaaa tcattactac agacaacaca 3360
tttgtgtctg gtaactgtga tgttgtaata ggaattgtca acaacacagt ttatgatcct 3420
ttgcaacctg aattagactc attcaaggag gagttagata aatattttaa gaatcataca 3480
tcaccagatg ttgatttagg tgacatctct ggcattaatg cttcagttgt aaacattcaa 3540
aaagaaattg accgcctcaa tgaggttgcc aagaatttaa atgaatctct catcgatctc 3600
caagaacttg gaaagtatga gcagtatata aaatggccat ggtacatttg gctaggtttt 3660
atagctggct tgattgccat agtaatggtg acaattatgc tttgctgtat gaccagttgc 3720
tgtagttgtc tcaagggctg ttgttcttgt ggatcctgct gcaaatttga tgaagacgac 3780
tctgagccag tgctcaaagg agtcaaatta cattacacat aa 3822
<210> 2
<211> 1273
<212> PRT
<213>人工序列
<400> 2
Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val
1 5 10 15
Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe
20 25 30
Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu
35 40 45
His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp
50 55 60
Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp
65 70 75 80
Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu
85 90 95
Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser
100 105 110
Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile
115 120 125
Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr
130 135 140
Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr
145 150 155 160
Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu
165 170 175
Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe
180 185 190
Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr
195 200 205
Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu
210 215 220
Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr
225 230 235 240
Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser
245 250 255
Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro
260 265 270
Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala
275 280 285
Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys
290 295 300
Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val
305 310 315 320
Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys
325 330 335
Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala
340 345 350
Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu
355 360 365
Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro
370 375 380
Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe
385 390 395 400
Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly
405 410 415
Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys
420 425 430
Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn
435 440 445
Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe
450 455 460
Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys
465 470 475 480
Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly
485 490 495
Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val
500 505 510
Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys
515 520 525
Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn
530 535 540
Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu
545 550 555 560
Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val
565 570 575
Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe
580 585 590
Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val
595 600 605
Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile
610 615 620
His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser
625 630 635 640
Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val
645 650 655
Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala
660 665 670
Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala
675 680 685
Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser
690 695 700
Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile
705 710 715 720
Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val
725 730 735
Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu
740 745 750
Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr
755 760 765
Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln
770 775 780
Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe
785 790 795 800
Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser
805 810 815
Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly
820 825 830
Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp
835 840 845
Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu
850 855 860
Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly
865 870 875 880
Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile
885 890 895
Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr
900 905 910
Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn
915 920 925
Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala
930 935 940
Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn
945 950 955 960
Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val
965 970 975
Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln
980 985 990
Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val
995 1000 1005
Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn
1010 1015 1020
Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu Gly Gln Ser Lys
1025 1030 1035
Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met Ser Phe Pro
1040 1045 1050
Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr Tyr Val
1055 1060 1065
Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys His
1070 1075 1080
Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn
1085 1090 1095
Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln
1100 1105 1110
Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val
1115 1120 1125
Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro
1130 1135 1140
Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn
1145 1150 1155
His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn
1160 1165 1170
Ala Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu
1175 1180 1185
Val Ala Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu
1190 1195 1200
Gly Lys Tyr Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu
1205 1210 1215
Gly Phe Ile Ala Gly Leu Ile Ala Ile Val Met Val Thr Ile Met
1220 1225 1230
Leu Cys Cys Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys
1235 1240 1245
Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro
1250 1255 1260
Val Leu Lys Gly Val Lys Leu His Tyr Thr
1265 1270
<210>3
<211> 508
<212> PRT
<213> 人工序列
<400> 3
Met Ser Ser Val Leu Lys Ala Tyr Glu Arg Phe Thr Leu Thr Gln Glu
1 5 10 15
Leu Gln Asp Gln Ser Glu Glu Gly Thr Ile Pro Pro Thr Thr Leu Lys
20 25 30
Pro Val Ile Arg Val Phe Ile Leu Thr Ser Asn Asn Pro Glu Leu Arg
35 40 45
Ser Arg Leu Leu Leu Phe Cys Leu Arg Ile Val Leu Ser Asn Gly Ala
50 55 60
Arg Asp Ser His Arg Phe Gly Ala Leu Leu Thr Met Phe Ser Leu Pro
65 70 75 80
Ser Ala Thr Met Leu Asn His Val Lys Leu Ala Asp Gln Ser Pro Glu
85 90 95
Ala Asp Ile Glu Arg Val Glu Ile Asp Gly Phe Glu Glu Gly Ser Phe
100 105 110
Arg Leu Ile Pro Asn Ala Arg Ser Gly Met Ser Arg Gly Glu Ile Asn
115 120 125
Ala Tyr Ala Ala Leu Ala Glu Asp Leu Pro Asp Thr Leu Asn His Ala
130 135 140
Thr Pro Phe Val Asp Ser Glu Val Glu Gly Thr Ala Trp Asp Glu Ile
145 150 155 160
Glu Thr Phe Leu Asp Met Cys Tyr Ser Val Leu Met Gln Ala Trp Ile
165 170 175
Val Thr Cys Lys Cys Met Thr Ala Pro Asp Gln Pro Ala Ala Ser Ile
180 185 190
Glu Lys Arg Leu Gln Lys Tyr Arg Gln Gln Gly Arg Ile Asn Pro Arg
195 200 205
Tyr Leu Leu Gln Pro Glu Ala Arg Arg Ile Ile Gln Asn Val Ile Arg
210 215 220
Lys Gly Met Val Val Arg His Phe Leu Thr Phe Glu Leu Gln Leu Ala
225 230 235 240
Arg Ala Gln Ser Leu Val Ser Asn Arg Tyr Tyr Ala Met Val Gly Asp
245 250 255
Val Gly Lys Tyr Ile Glu Asn Cys Gly Met Gly Gly Phe Phe Leu Thr
260 265 270
Leu Lys Tyr Ala Leu Gly Thr Arg Trp Pro Thr Leu Ala Leu Ala Ala
275 280 285
Phe Ser Gly Glu Leu Thr Lys Leu Lys Ser Leu Met Ala Leu Tyr Gln
290 295 300
Thr Leu Gly Glu Gln Ala Arg Tyr Leu Ala Leu Leu Glu Ser Pro His
305 310 315 320
Leu Met Asp Phe Ala Ala Ala Asn Tyr Pro Leu Leu Tyr Ser Tyr Ala
325 330 335
Met Gly Ile Gly Tyr Val Leu Asp Val Asn Met Arg Asn Tyr Ala Phe
340 345 350
Ser Arg Ser Tyr Met Asn Lys Thr Tyr Phe Gln Leu Gly Met Glu Thr
355 360 365
Ala Arg Lys Gln Gln Gly Ala Val Asp Met Arg Met Ala Glu Asp Leu
370 375 380
Gly Leu Thr Gln Ala Glu Arg Thr Glu Met Ala Asn Thr Leu Ala Lys
385 390 395 400
Leu Thr Thr Ala Asn Arg Gly Ala Asp Thr Arg Gly Gly Val Asn Pro
405 410 415
Phe Ser Ser Val Thr Gly Thr Thr Gln Val Pro Ala Ala Ala Thr Gly
420 425 430
Asp Thr Leu Glu Ser Tyr Met Ala Ala Asp Arg Leu Arg Gln Arg Tyr
435 440 445
Ala Asp Ala Gly Thr His Asp Asp Glu Met Pro Pro Leu Glu Glu Glu
450 455 460
Glu Glu Asp Asp Thr Ser Ala Gly Pro Arg Thr Gly Pro Thr Leu Glu
465 470 475 480
Gln Val Ala Leu Asp Ile Gln Asn Ala Ala Val Gly Ala Pro Ile His
485 490 495
Thr Asp Asp Leu Asn Ala Ala Leu Gly Asp Leu Asp
500 505
<210>4
<211> 392
<212> PRT
<213> 人工序列
<400> 4
Met Asp Pro Thr Asp Leu Ser Phe Ser Pro Asp Glu Ile Asn Lys Leu
1 5 10 15
Ile Glu Thr Gly Leu Asn Thr Val Glu Tyr Leu Thr Ser Gln Gln Val
20 25 30
Thr Gly Thr Ser Ser Leu Gly Lys Asn Thr Ile Pro Pro Gly Val Thr
35 40 45
Gly Leu Pro Thr Asn Ala Ala Glu Ala Lys Ile Gln Glu Ser Thr Asn
50 55 60
His Gln Lys Gly Ser Val Gly Gly Gly Ala Lys Pro Lys Lys Pro Arg
65 70 75 80
Pro Lys Ile Ala Ile Val Pro Ala Asp Asp Lys Thr Val Pro Gly Lys
85 90 95
Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Pro Ser Thr Gln
100 105 110
Thr Val Leu Asp Leu Ser Gly Lys Thr Leu Pro Ser Gly Ser Tyr Lys
115 120 125
Gly Val Lys Leu Ala Asn Phe Gly Lys Glu Asn Leu Met Thr Arg Phe
130 135 140
Ile Glu Glu Pro Arg Glu Asn Pro Ile Ala Thr Asn Ser Pro Ile Asp
145 150 155 160
Phe Lys Arg Gly Ala Gly Ile Pro Ala Gly Ser Ile Glu Gly Ser Thr
165 170 175
Gln Ser Asp Gly Trp Glu Met Lys Ser Arg Ser Leu Ser Gly Ala Ile
180 185 190
His Pro Val Leu Gln Ser Pro Leu Gln Gln Gly Asp Leu Asn Ala Leu
195 200 205
Val Thr Ser Val Gln Ser Leu Ala Leu Asn Val Asn Glu Ile Leu Asn
210 215 220
Thr Val Arg Asn Leu Asp Ser Arg Met Asn Gln Leu Glu Thr Lys Val
225 230 235 240
Asp Arg Ile Leu Ser Ser Gln Ser Leu Ile Gln Thr Ile Lys Asn Asp
245 250 255
Ile Val Gly Leu Lys Ala Gly Met Ala Thr Leu Glu Gly Met Ile Thr
260 265 270
Thr Val Lys Ile Met Asp Pro Gly Val Pro Ser Asn Ile Thr Val Glu
275 280 285
Asp Val Arg Lys Lys Leu Ser Asn His Ala Val Val Val Pro Glu Ser
290 295 300
Phe Asn Asp Ser Phe Leu Thr Gln Ser Glu Asp Val Ile Ser Leu Asp
305 310 315 320
Glu Leu Ala Arg Pro Thr Ala Thr Ser Val Lys Lys Ile Val Arg Lys
325 330 335
Val Pro Pro Gln Lys Asp Leu Thr Gly Leu Lys Ile Thr Leu Glu Gln
340 345 350
Leu Ala Lys Asp Cys Ile Ser Lys Pro Lys Met Arg Glu Glu Tyr Leu
355 360 365
Leu Lys Ile Asn Gln Ala Ser Ser Glu Ala Gln Leu Ile Asp Leu Lys
370 375 380
Lys Ala Ile Ile Arg Ser Ala Ile
385 390
<210> 5
<211> 2255
<212> PRT
<213> 人工序列
<400> 5
Met Ala Gly Ser Arg Glu Ile Leu Leu Pro Glu Val His Leu Asn Ser
1 5 10 15
Pro Ile Val Lys His Lys Leu Tyr Tyr Tyr Ile Leu Leu Gly Asn Leu
20 25 30
Pro Asn Glu Ile Asp Ile Asp Asp Leu Gly Pro Leu His Asn Gln Asn
35 40 45
Trp Asn Gln Ile Ala His Glu Glu Ser Asn Leu Ala Gln Arg Leu Val
50 55 60
Asn Val Arg Asn Phe Leu Ile Thr His Ile Ser Asp Leu Arg Lys Gly
65 70 75 80
His Trp Gln Glu Tyr Val Asn Val Ile Leu Trp Pro Arg Ile Leu Pro
85 90 95
Leu Ile Pro Asp Phe Lys Ile Asn Asp Gln Leu Pro Leu Leu Lys Asn
100 105 110
Trp Asp Lys Leu Val Lys Glu Ser Cys Ser Val Ile Asn Ala Gly Thr
115 120 125
Ser Gln Cys Ile Gln Asn Leu Ser Tyr Gly Leu Thr Gly Arg Gly Asn
130 135 140
Leu Phe Thr Arg Ser Arg Glu Leu Ser Gly Asp Arg Arg Asp Ile Asp
145 150 155 160
Leu Lys Thr Val Val Ala Ala Trp His Asp Ser Asp Trp Lys Arg Ile
165 170 175
Ser Asp Phe Trp Ile Met Ile Lys Phe Gln Met Arg Gln Leu Ile Val
180 185 190
Arg Gln Thr Asp His Asn Asp Pro Asp Leu Ile Thr Tyr Ile Glu Asn
195 200 205
Arg Glu Gly Ile Ile Ile Ile Thr Pro Glu Leu Val Ala Leu Phe Asn
210 215 220
Thr Glu Asn His Thr Leu Thr Tyr Met Thr Phe Glu Ile Val Leu Met
225 230 235 240
Val Ser Asp Met Tyr Glu Gly Arg His Asn Ile Leu Ser Leu Cys Thr
245 250 255
Val Ser Thr Tyr Leu Asn Pro Leu Lys Lys Arg Ile Lys Tyr Leu Leu
260 265 270
Ser Leu Val Asp Asn Leu Ala Phe Gln Ile Gly Asp Ala Val Tyr Asn
275 280 285
Ile Ile Ala Leu Leu Glu Ser Phe Val Tyr Ala Gln Leu Gln Met Ser
290 295 300
Asp Pro Ile Pro Glu Leu Arg Gly Gln Phe His Ala Phe Val Cys Ser
305 310 315 320
Glu Ile Leu Asp Ala Leu Arg Gly Thr Asn Ser Phe Thr Gln Asp Glu
325 330 335
Ser Arg Thr Val Thr Thr Asn Leu Ile Ser Pro Phe Gln Asp Leu Thr
340 345 350
Pro Asp Leu Thr Ala Glu Leu Leu Cys Ile Met Arg Leu Trp Gly His
355 360 365
Pro Met Leu Thr Ala Ser Gln Ala Ala Gly Lys Val Arg Glu Ser Met
370 375 380
Cys Ala Gly Lys Val Leu Asp Phe Pro Thr Ile Met Lys Thr Leu Ala
385 390 395 400
Phe Phe His Thr Ile Leu Ile Asn Gly Tyr Arg Arg Lys His His Gly
405 410 415
Val Trp Pro Pro Leu Asn Leu Pro Gly Asn Ala Ser Lys Gly Leu Thr
420 425 430
Glu Leu Met Asn Asp Asn Thr Glu Ile Ser Tyr Glu Phe Thr Leu Lys
435 440 445
His Trp Lys Glu Ile Ser Leu Ile Lys Phe Lys Lys Cys Phe Asp Ala
450 455 460
Asp Ala Gly Glu Glu Leu Ser Ile Phe Met Lys Asp Lys Ala Ile Ser
465 470 475 480
Ala Pro Lys Gln Asp Trp Met Ser Val Phe Arg Arg Ser Leu Ile Lys
485 490 495
Gln Arg His Gln His His Gln Val Pro Leu Pro Asn Pro Phe Asn Arg
500 505 510
Arg Leu Leu Leu Asn Phe Leu Gly Asp Asp Lys Phe Asp Pro Asn Val
515 520 525
Glu Leu Gln Tyr Val Thr Ser Gly Glu Tyr Leu His Asp Asp Thr Phe
530 535 540
Cys Ala Ser Tyr Ser Leu Lys Glu Lys Glu Ile Lys Pro Asp Gly Arg
545 550 555 560
Ile Phe Ala Lys Leu Thr Lys Arg Met Arg Ser Cys Gln Val Ile Ala
565 570 575
Glu Ser Leu Leu Ala Asn His Ala Gly Lys Leu Met Lys Glu Asn Gly
580 585 590
Val Val Met Asn Gln Leu Ser Leu Thr Lys Ser Leu Leu Thr Met Ser
595 600 605
Gln Ile Gly Ile Ile Ser Glu Lys Ala Arg Lys Ser Thr Arg Asp Asn
610 615 620
Ile Asn Gln Pro Gly Phe Gln Asn Ile Gln Arg Asn Lys Ser His His
625 630 635 640
Ser Lys Gln Val Asn Gln Arg Asp Pro Ser Asp Asp Phe Glu Leu Ala
645 650 655
Ala Ser Phe Leu Thr Thr Asp Leu Lys Lys Tyr Cys Leu Gln Trp Arg
660 665 670
Tyr Gln Thr Ile Ile Pro Phe Ala Gln Ser Leu Asn Arg Met Tyr Gly
675 680 685
Tyr Pro His Leu Phe Glu Trp Ile His Leu Arg Leu Met Arg Ser Thr
690 695 700
Leu Tyr Val Gly Asp Pro Phe Asn Pro Pro Ala Asp Thr Ser Gln Phe
705 710 715 720
Asp Leu Asp Lys Val Ile Asn Gly Asp Ile Phe Ile Val Ser Pro Arg
725 730 735
Gly Gly Ile Glu Gly Leu Cys Gln Lys Ala Trp Thr Met Ile Ser Ile
740 745 750
Ser Val Ile Ile Leu Ser Ala Thr Glu Ser Gly Thr Arg Val Met Ser
755 760 765
Met Val Gln Gly Asp Asn Gln Ala Ile Ala Val Thr Thr Arg Val Pro
770 775 780
Arg Ser Leu Pro Thr Leu Glu Lys Lys Thr Ile Ala Phe Arg Ser Cys
785 790 795 800
Asn Leu Phe Phe Glu Arg Leu Lys Cys Asn Asn Phe Gly Leu Gly His
805 810 815
His Leu Lys Glu Gln Glu Thr Ile Ile Ser Ser His Phe Phe Val Tyr
820 825 830
Ser Lys Arg Ile Phe Tyr Gln Gly Arg Ile Leu Thr Gln Ala Leu Lys
835 840 845
Asn Ala Ser Lys Leu Cys Leu Thr Ala Asp Val Leu Gly Glu Cys Thr
850 855 860
Gln Ser Ser Cys Ser Asn Leu Ala Thr Thr Val Met Arg Leu Thr Glu
865 870 875 880
Asn Gly Val Glu Lys Asp Ile Cys Phe Tyr Leu Asn Ile Tyr Met Thr
885 890 895
Ile Lys Gln Leu Ser Tyr Asp Ile Ile Phe Pro Gln Val Ser Ile Pro
900 905 910
Gly Asp Gln Ile Thr Leu Glu Tyr Ile Asn Asn Pro His Leu Val Ser
915 920 925
Arg Leu Ala Leu Leu Pro Ser Gln Leu Gly Gly Leu Asn Tyr Leu Ser
930 935 940
Cys Ser Arg Leu Phe Asn Arg Asn Ile Gly Asp Pro Val Val Ser Ala
945 950 955 960
Val Ala Asp Leu Lys Arg Leu Ile Lys Ser Gly Cys Met Asp Tyr Trp
965 970 975
Ile Leu Tyr Asn Leu Leu Gly Arg Lys Pro Gly Asn Gly Ser Trp Ala
980 985 990
Thr Leu Ala Ala Asp Pro Tyr Ser Ile Asn Ile Glu Tyr Gln Tyr Pro
995 1000 1005
Pro Thr Thr Ala Leu Lys Arg His Thr Gln Gln Ala Leu Met Glu
1010 1015 1020
Leu Ser Thr Asn Pro Met Leu Arg Gly Ile Phe Ser Asp Asn Ala
1025 1030 1035
Gln Ala Glu Glu Asn Asn Leu Ala Arg Phe Leu Leu Asp Arg Glu
1040 1045 1050
Val Ile Phe Pro Arg Val Ala His Ile Ile Ile Glu Gln Thr Ser
1055 1060 1065
Val Gly Arg Arg Lys Gln Ile Gln Gly Tyr Leu Asp Ser Thr Arg
1070 1075 1080
Ser Ile Met Ser Lys Ser Leu Glu Ile Lys Pro Leu Ser Asn Arg
1085 1090 1095
Lys Leu Asn Glu Ile Leu Asp Tyr Asn Ile Asn Tyr Leu Ala Tyr
1100 1105 1110
Asn Leu Ala Leu Leu Lys Asn Ala Ile Glu Pro Pro Thr Tyr Leu
1115 1120 1125
Lys Ala Met Thr Leu Glu Thr Cys Ser Ile Asp Ile Ala Arg Ser
1130 1135 1140
Leu Arg Lys Leu Ser Trp Ala Pro Leu Leu Gly Gly Arg Asn Leu
1145 1150 1155
Glu Gly Leu Glu Thr Pro Asp Pro Ile Glu Ile Thr Ala Gly Ala
1160 1165 1170
Leu Ile Val Gly Ser Gly Tyr Cys Glu Gln Cys Ala Ala Gly Asp
1175 1180 1185
Asn Arg Phe Thr Trp Phe Phe Leu Pro Ser Gly Ile Glu Ile Gly
1190 1195 1200
Gly Asp Pro Arg Asp Asn Pro Pro Ile Arg Val Pro Tyr Ile Gly
1205 1210 1215
Ser Arg Thr Asp Glu Arg Arg Val Ala Ser Met Ala Tyr Ile Arg
1220 1225 1230
Gly Ala Ser Ser Ser Leu Lys Ala Val Leu Arg Leu Ala Gly Val
1235 1240 1245
Tyr Ile Trp Ala Phe Gly Asp Thr Leu Glu Asn Trp Ile Asp Ala
1250 1255 1260
Leu Asp Leu Ser His Thr Arg Val Asn Ile Thr Leu Glu Gln Leu
1265 1270 1275
Gln Ser Leu Thr Pro Leu Pro Thr Ser Ala Asn Leu Thr His Arg
1280 1285 1290
Leu Asp Asp Gly Thr Thr Thr Leu Lys Phe Thr Pro Ala Ser Ser
1295 1300 1305
Tyr Thr Phe Ser Ser Phe Thr His Ile Ser Asn Asp Glu Gln Tyr
1310 1315 1320
Leu Thr Ile Asn Asp Lys Thr Ala Asp Ser Asn Ile Ile Tyr Gln
1325 1330 1335
Gln Leu Met Ile Thr Gly Leu Gly Ile Leu Glu Thr Trp Asn Asn
1340 1345 1350
Pro Pro Ile Asn Arg Thr Phe Glu Glu Ser Thr Leu His Leu His
1355 1360 1365
Thr Gly Ala Ser Cys Cys Val Arg Pro Val Asp Ser Cys Ile Ile
1370 1375 1380
Ser Glu Ala Leu Thr Val Lys Pro His Ile Thr Val Pro Tyr Ser
1385 1390 1395
Asn Lys Phe Val Phe Asp Glu Asp Pro Leu Ser Glu Tyr Glu Thr
1400 1405 1410
Ala Lys Leu Glu Ser Leu Ser Phe Gln Ala Gln Leu Gly Asn Ile
1415 1420 1425
Asp Ala Val Asp Met Thr Gly Lys Leu Thr Leu Leu Ser Gln Phe
1430 1435 1440
Thr Ala Arg Gln Ile Ile Asn Ala Ile Thr Gly Leu Asp Glu Ser
1445 1450 1455
Val Ser Leu Thr Asn Asp Ala Ile Val Ala Ser Asp Tyr Val Ser
1460 1465 1470
Asn Trp Ile Ser Glu Cys Met Tyr Thr Lys Leu Asp Glu Leu Phe
1475 1480 1485
Met Tyr Cys Gly Trp Glu Leu Leu Leu Glu Leu Ser Tyr Gln Met
1490 1495 1500
Tyr Tyr Leu Arg Val Val Gly Trp Ser Asn Ile Val Asp Tyr Ser
1505 1510 1515
Tyr Met Ile Leu Arg Arg Ile Pro Gly Ala Ala Leu Asn Asn Leu
1520 1525 1530
Ala Ser Thr Leu Ser His Pro Lys Leu Phe Arg Arg Ala Ile Asn
1535 1540 1545
Leu Asp Ile Val Ala Pro Leu Asn Ala Pro His Phe Ala Ser Leu
1550 1555 1560
Asp Tyr Ile Lys Met Ser Val Asp Ala Ile Leu Trp Gly Cys Lys
1565 1570 1575
Arg Val Ile Asn Val Ile Ser Asn Gly Gly Asp Leu Glu Leu Val
1580 1585 1590
Val Thr Ser Glu Asp Ser Leu Ile Leu Ser Asp Arg Ser Met Asn
1595 1600 1605
Leu Ile Ala Arg Lys Leu Thr Leu Leu Ser Leu Ile His His Asn
1610 1615 1620
Gly Leu Glu Leu Pro Lys Ile Lys Gly Phe Ser Pro Asp Glu Lys
1625 1630 1635
Cys Phe Ala Leu Thr Glu Phe Leu Arg Lys Val Val Asn Ser Gly
1640 1645 1650
Leu Ser Ser Ile Glu Asn Leu Ser Asn Phe Met Tyr Asn Val Glu
1655 1660 1665
Asn Pro Arg Leu Ala Ala Phe Ala Ser Asn Asn Tyr Tyr Leu Thr
1670 1675 1680
Arg Lys Leu Leu Asn Ser Ile Arg Asp Thr Glu Ser Gly Gln Val
1685 1690 1695
Ala Val Thr Ser Tyr Tyr Glu Ser Leu Glu Tyr Ile Asp Ser Leu
1700 1705 1710
Lys Leu Thr Pro His Val Pro Gly Thr Ser Cys Ile Glu Asp Asp
1715 1720 1725
Ser Leu Cys Thr Asn Asp Tyr Ile Ile Trp Ile Ile Glu Ser Asn
1730 1735 1740
Ala Asn Leu Glu Lys Tyr Pro Ile Pro Asn Ser Pro Glu Asp Asp
1745 1750 1755
Ser Asn Phe His Asn Phe Lys Leu Asn Ala Pro Ser His His Thr
1760 1765 1770
Leu Arg Pro Leu Gly Leu Ser Ser Thr Ala Trp Tyr Lys Gly Ile
1775 1780 1785
Ser Cys Cys Arg Tyr Leu Glu Arg Leu Lys Leu Pro Gln Gly Asp
1790 1795 1800
His Leu Tyr Ile Ala Glu Gly Ser Gly Ala Ser Met Thr Ile Ile
1805 1810 1815
Glu Tyr Leu Phe Pro Gly Arg Lys Ile Tyr Tyr Asn Ser Leu Phe
1820 1825 1830
Ser Ser Gly Asp Asn Pro Pro Gln Arg Asn Tyr Ala Pro Met Pro
1835 1840 1845
Thr Gln Phe Ile Glu Ser Val Pro Tyr Lys Leu Trp Gln Ala His
1850 1855 1860
Thr Asp Gln Tyr Pro Glu Ile Phe Glu Asp Phe Ile Pro Leu Trp
1865 1870 1875
Asn Gly Asn Ala Ala Met Thr Asp Ile Gly Met Thr Ala Cys Val
1880 1885 1890
Glu Phe Ile Ile Asn Arg Val Gly Pro Arg Thr Cys Ser Leu Val
1895 1900 1905
His Val Asp Leu Glu Ser Ser Ala Ser Leu Asn Gln Gln Cys Leu
1910 1915 1920
Ser Lys Pro Ile Ile Asn Ala Ile Ile Thr Ala Thr Thr Val Leu
1925 1930 1935
Cys Pro His Gly Val Leu Ile Leu Lys Tyr Ser Trp Leu Pro Phe
1940 1945 1950
Thr Arg Phe Ser Thr Leu Ile Thr Phe Leu Trp Cys Tyr Phe Glu
1955 1960 1965
Arg Ile Thr Val Leu Arg Ser Thr Tyr Ser Gly Pro Ala Asn His
1970 1975 1980
Glu Val Tyr Leu Ile Cys Ile Leu Ala Asn Asn Phe Ala Phe Gln
1985 1990 1995
Thr Val Ser Gln Ala Thr Gly Met Ala Met Thr Leu Thr Asp Gln
2000 2005 2010
Gly Phe Thr Leu Ile Ser Pro Glu Arg Ile Asn Gln Tyr Trp Asp
2015 2020 2025
Gly His Leu Lys Gln Glu Arg Ile Val Ala Glu Ala Ile Asp Lys
2030 2035 2040
Val Val Leu Gly Glu Asp Ala Leu Phe Asn Ser Ser Asp Asn Glu
2045 2050 2055
Leu Ile Leu Lys Cys Gly Gly Thr Pro Asn Ala Arg Asn Leu Ile
2060 2065 2070
Asp Ile Glu Pro Val Ala Thr Phe Ile Glu Phe Glu Gln Leu Ile
2075 2080 2085
Cys Thr Met Leu Thr Thr His Leu Lys Glu Ile Ile Asp Ile Thr
2090 2095 2100
Arg Ser Gly Thr Gln Asp Tyr Glu Ser Leu Leu Leu Thr Pro Tyr
2105 2110 2115
Asn Leu Gly Leu Leu Gly Lys Ile Ser Thr Ile Val Arg Leu Leu
2120 2125 2130
Thr Glu Arg Ile Leu Asn His Thr Ile Arg Asn Trp Leu Ile Leu
2135 2140 2145
Pro Pro Ser Leu Arg Met Ile Val Lys Gln Asp Leu Glu Phe Gly
2150 2155 2160
Ile Phe Arg Ile Thr Ser Ile Leu Asn Ser Asp Arg Phe Leu Lys
2165 2170 2175
Leu Ser Pro Asn Arg Lys Tyr Leu Ile Thr Gln Leu Thr Ala Gly
2180 2185 2190
Tyr Ile Arg Lys Leu Ile Glu Gly Asp Cys Asn Ile Asp Leu Thr
2195 2200 2205
Arg Pro Ile Gln Lys Gln Ile Trp Lys Ala Leu Gly Cys Val Val
2210 2215 2220
Tyr Cys His Asp Pro Val Asp Gln Arg Glu Ser Thr Glu Phe Ile
2225 2230 2235
Asp Ile Asn Ile Asn Glu Glu Ile Asp Leu Gly Ile Asp Gly Glu
2240 2245 2250
Glu Ile
2255
<210> 6
<211> 15246
<212> DNA
<213> 人工序列
<400> 6
accaagggga aaatgaagtg gtgactcaaa tcatcaaaga ccctcgagat tacataggtc 60
tggaacttat ggccttcgtg accgacctcg agtcagagta gttcaataag gacctatcaa 120
gtttgggcaa tttttcgtcc ccgacacaaa aatgtcatcc gtgcttaaag catatgagcg 180
attcacactc actcaagaac tgcaagatca gagtgaggaa ggtacaatcc cacctacaac 240
actaaaaccg gtaatcaggg tatttatact aacctctaat aacccagagc taagatcccg 300
gcttcttcta ttctgcctac ggattgttct cagtaatggt gcaagggatt cccatcgctt 360
tggagcatta cttacaatgt tttcgctacc atcagccaca atgctcaatc atgtcaaatt 420
agctgaccag tcaccagaag ctgatatcga aagggtagag atcgatggct ttgaggaggg 480
atcattccgc ttaatcccca atgctcgttc aggtatgagc cgtggagaga tcaatgccta 540
tgctgcactt gcagaagatc tacctgacac actaaaccat gcaacacctt ttgttgattc 600
cgaagtcgag ggaactgcat gggatgagat tgagactttc ttagatatgt gttacagtgt 660
cctaatgcag gcatggatag tgacttgcaa gtgcatgact gcgccagacc aacctgctgc 720
ttctattgag aaacgcctgc aaaaatatcg tcagcaaggc aggatcaacc cgagatatct 780
cctgcaaccg gaggctcgaa gaataatcca gaatgtaatc cgaaagggaa tggtggtcag 840
acatttcctc acctttgaac tgcagcttgc ccgagcacaa agccttgtat caaataggta 900
ttatgctatg gtaggggatg ttggaaagta tatagagaat tgtggaatgg gaggcttctt 960
tttgacacta aaatatgcat taggaaccag atggcccaca cttgctttag ctgcattttc 1020
aggagagcta acaaagctaa agtccctcat ggcattatac cagacccttg gtgagcaggc 1080
ccgatatttg gccctattgg agtcaccaca tttgatggat tttgctgcag caaactaccc 1140
actgctatat agctatgcta tgggaatagg ctatgtgtta gatatcaaca tgaggaacta 1200
cgctttctcc agatcataca tgaataagac atatttccaa ttgggaatgg aaactgcaag 1260
aaaacaacag ggtgcagttg acatgaggat ggcagaagat ctcggtctaa ctcaagccga 1320
acgcaccgag atggcaaata cacttgccaa attgaccaca gcaaatcgag gggcagacac 1380
caggggagga gtcaacccgt tctcatctat cactgggaca actcaggtgc ccgctgcagc 1440
aacaggtgac acattcgaga gttacatggc agcggatcga ctgaggcaga gatatgctga 1500
tgcaggcacc cacgatgatg agatgccacc attggaagag gaggaagagg acgacacatc 1560
tgcaggtcca cgcactggac taactcttga acaagtggcc ttggacatcc agaacgcagc 1620
agttggagct cccatccata cagatgacct gaatgccgca ctgggtgatc ttgacatcta 1680
gacaattcag atcccaatct taaatcgaca cacctaattg accagttaga tggaactaca 1740
gtggattcca tgaggttcct gcctaccatc ggcttttaag aaaaaaatag gcccggacgg 1800
gttagcaaca agcgaccgcc gatgccaata acacaatcca caatctacaa tggatcccac 1860
tgatctgagc ttctccccag atgagatcaa taagctcata gagacaggcc tgaatactgt 1920
ggagtattta acttcccaac aagtcacagg aacatcctct cttggaaaga atacaatacc 1980
accaggggtc acaggactac caaccaatgc tgcagaggca aagatccaag agtcaaccaa 2040
ccatcagaag ggttcagttg gtgggggcgc aaaaccaaag aaaccgcgac caaaaattgc 2100
cattgtgcca gcagatgaca aaacggtgcc cggaaagccg atcccaaacc ctctattagg 2160
tctggactcc accccgagca cccaaactgt gcttgatcta agtgggaaaa cattaccatc 2220
aggatcctat aagggggtta aacttgcgaa ctttggaaaa gaaaatctga tgacacggtt 2280
catcgaggaa cccagagaga atcctatcgc aaccaattcc cccatcgatt ttaagagggg 2340
cagggatacc ggcgggttcc atagaaggga gtactcaatc ggatgggtgg gagatgaagt 2400
caaggtcact gagtggtgca atccatcctg ttctccaatc accgctgcag caaggcgatt 2460
tgaatgcact tgtcaccagt gtccagtcac ttgctctgaa tgtgaacgag atacttaata 2520
cagtgagaaa tttggactct cggatgaatc aactggagac aaaagtagat cgcattctct 2580
catctcagtc tctaatccag accatcaaga atgacatagt tggacttaaa gcagggatgg 2640
ctactttaga aggaatgatt acaactgtga aaatcatgga tccgggagtt cccagtaata 2700
ttactgtgga agatgtacgc aagaaactaa gtaaccatgc tgttgttgtg ccagaatcat 2760
tcaatgatag tttcttgact caatctgaag atgtaatttc acttgatgag ttggctcgac 2820
caactgcaac aagtgttaag aagattgtca ggaaggttcc tcctcagaag gatctgactg 2880
gattgaagat cacactagag caattggcaa aggattgcat cagcaaaccg aagatgaggg 2940
aagagtatct cctcaaaatc aaccaggctt ccagtgaggc tcagctaatt gacctcaaga 3000
aagcaatcat ccgcagtgca atttgatcaa gaaacaccca attacactac actggtatga 3060
cactgtacta accctgaggg ttttagaaaa aacgattaac gataaataag cccgaacact 3120
acacaccacc cgaggcagcc atgccatcca tcagcatccc cgcagacccc accaatccac 3180
gtcaatcaat aaaagcgttc ccaattgtga tcaaccgtga tgggggtgag aaaggtcgct 3240
tggttaaaca actacgcaca acctacttga atgacctaga tactcatgag ccactggtga 3300
cattcgtaaa tacttatgga ttcatctacg aacaggatcg gggaaatacc attgtcggag 3360
aggatcaaca tgggaagaaa agagaggctg tgactgctgc aatggttacc cttggatgtg 3420
ggcctaatct accatcatta gggaatgtcc tgggacaact gagtgaattc caggtcattg 3480
ttaggaagac atccagcaaa gcggaagaga tggtctttga aattgttaag tatccgagaa 3540
tatttcgggg tcatacatta atccagaaag gactagtctg tgtctccgca gaaaaatttg 3600
ttaagtcacc agggaaagta caatctggaa tggactatct cttcattccg acatttctgt 3660
cagtgactta ctgtccagct gcaatcaaat ttcaggtact tggccccatg ttgaaaatga 3720
gatcaagata cactcagagc ttacaacttg aactaatgat aagaatcctg tgtaagcccg 3780
attcgccact tatgaaggtc catatccctg acaaggaagg aagaggatgt cttgtatcag 3840
tatggttgca tgtatgcaat atcttcaaat caggaaacaa gaatggcagt gagtggcagg 3900
aatactggat gagaaagtgt gctaacatgc aacttgaagt gtcgattgca gatatgtggg 3960
gaccaactat cataattcat gccagaggtc acattcccaa aagtgctaag ttgttttttg 4020
gaaagggtgg atggagctgc catccacttc acgaagttgt tccaagtgtc actaagacac 4080
tatggtccgt gggctgtgag attacaaagg cgaaggcaat aatacaagag agtagcatct 4140
ctcttctcgt ggagactact gacatcataa gtccaaaagt caaaatttca tctaagcatc 4200
gccgctttgg gaaatcaaat tggggtctgt tcaagaaaac caaatcactg cccaacctga 4260
cggcgctgga atgactgacc cccaatcgag actacaccac ctcaaactat aggtgggtgg 4320
tacctcagtg attaatctcg taagcactga tcgtaggcta caacacacta atattatcca 4380
gattagagag cttaattagc tctgtattaa taataacact actattccaa taactggaat 4440
caccagcttg atttatctcc aaaatgattc aaagaaaaca aatcatatta agactatcct 4500
aagcacgaac ccatatcgtc cttcaaatca tgggtactat aattcaattt ctggtggtct 4560
cctgtctatt ggcaggagca ggcagtcttg atccagcagc cctcatgcaa atcggtgtca 4620
ttccaacaaa tgtccggcaa cttatgtatt atactgaggc ctcatcagca ttcattgttg 4680
tgaagttaat gcctacaatt gactcgccga ttagtggatg taatataaca tcaatttcaa 4740
gctataatgc aacagtgaca aaactcctac agccgatcgg tgagaatttg gagacgatta 4800
ggaaccagtt gattccaact cggaggagac gccggtttgc aggggtggtg attggattag 4860
ctgcattagg agtagctact gccgcacagg tcactgccgc agtagcacta gtaaaggcaa 4920
atgaaaatgc tgcggctata ctcaatctca aaaatgcaat ccaaaaaaca aatgcagcag 4980
ttgcagatgt ggtccaggcc acacaatcac taggaacggc agttcaagca gttcaagatc 5040
acataaacag tgtggtaagt ccagcaatta cagcagccaa ttgtaaagcc caagatgcta 5100
tcattggctc aatcctcaat ctctatttga ccgagttgac aactatcttc cacaatcaaa 5160
ttacaaaccc tgcattgagt cctattacaa ttcaagcttt aaggatccta ctagggagta 5220
ccttgccgac tgtggtcgaa aaatctttca atacccagat aagtgcggct gagcttctct 5280
catcagggtt attgacaggc cagattgtgg gattagattt gacctatatg cagatggtca 5340
taaaaattga gctgccaact ttagctgtac aacctgcaac ccagatcata gatctggcca 5400
ccatttctgc attcattaac aatcaagaag tcatggccca attaccaaca cgtgttattg 5460
tgactggcag cttgatccaa gcctatcccg catcgcaatg cactattaca cccaacactg 5520
tgtactgtag gtataatgat gcccgagtac tctcagatga tacgatggct tgcctccaag 5580
gtaacttgac aagatgcacc ttctctccag tggttgggag ctttctcact cgattcgtgc 5640
tgttcgatgg aatagtttat gcaaattgca ggtcgatgtt gtgcaagtgc atgcagcctg 5700
ctgctgtgat cctacagccg agttcatccc ctgtaactgt cattgacatg tacaaatgtg 5760
tgagtctgca gcttgacaat ctcagattca ccatcactca attggccaat gtaacctaca 5820
atagcaccat caagcttgaa acatcccaga tcttgcctat tgctccgttg gatatatccc 5880
agaatctagc tgcggtgaat aagagtctaa gtgatgcact acaacactta gcacaaagtg 5940
acacatacct ttctgcaatc acatcagcta cgactacaag tgtattatcc ataatagcaa 6000
tctgtcttgg atcgttaggt ttaatattaa taatcttgct cagtgtagtt gtgtggaagt 6060
tattgaccat tgtcgctgct aatcgaaata gaatggagaa ttttgtttat cataattcag 6120
cattccacca ctcacgatct gatctcagtg agaaaaatca acctgcaact cttggaacaa 6180
gataagacag taatccatta gtaattttta agaaaaaaac gataggaccg aaactagtat 6240
tgaaagaacc gtctcggtca atctaggtaa tcgagctgat accgtctcgg aaagctcaaa 6300
tcatgctgcc tgatccggaa gatccggaaa gcaaaaaagc tacaaggaga acaggaaacc 6360
taattatctg cttcctattc atcttctttc cgtttgtaaa cttcattgtt ccaactctaa 6420
gacacttgct gtcctaacac ctgctatagg ctatccactg catcatctct cctgccatac 6480
ttcctactca catcatatct attttaaaga aaaaagaggc ccgaacacta atcgtgccgg 6540
cagtgccact gcacacacaa cactacacat acaatacact acaatggttg cagaagatgc 6600
ccctgttagg ggcacttgcc gagtattatt tcgaacaaca actttaattt ttctatgcac 6660
actattagca ttaagcatct ctatccttta tgagagttta ataacccaaa agcaaatcat 6720
gagccaagca ggctcaactg gatctaattc tagattagga agtatcactg atcttcttaa 6780
taatattctc tctgtcgcaa atcagattat atataactct gcagtcgctc tacctctaca 6840
attggacact cttgaatcaa cactccttac agccattaag tctcttcaaa caagtgacaa 6900
gctagaacag aactgctcgt ggggtgctgc actgattaat gataatagat acattaatgg 6960
catcaatcag ttctatttct caattgctga gggtcgcaag ctgacacttg gcccacttct 7020
taatatacct agtttcattc caactgccac gacaccagag ggctgcacca ggatcccatc 7080
attctcgctc accaagacac actggtgtta tacacacaat gttatcctga atggatgcca 7140
ggatcatgta tcctcaaatc aatttgtttc catgggaatc attgaaccca cttctgccgg 7200
gtttccatcc cttcgaaccc taaagactct atatctcagc gatggggtca atcgtaagag 7260
ctgctctatc agtacagttc cggggggttg tatgatgtac tgtttcgtct ctactcaacc 7320
agagagggat gactactttt ctaccgctcc tccagaacaa cgaattatta taatgtacta 7380
taatgataca atcgtagagc gcataattaa tccacccggg gtactagatg tatgggcaac 7440
attgacccca ggaacaggaa gcggggtata ttatttaggt tgggtactct ttccaatata 7500
tggcggcgtg attaaagata cgagtttatg gaataatcaa gcaaataaat actttatccc 7560
ccagatggtt gctgctctct gctcacaaaa ccaggcaact caagtccaaa atgctaagtc 7620
atcatactat agcagctggt ttggcaatcg aatgattcag tctgggatcc tggcatgtcc 7680
tcttcaacag gatctaacca atgagtgttt agttctgccc ttttctaatg atcaggtgct 7740
tatgggtgct gaagggagat tatacatgta tggtgactcg gtgtattact accaaagaag 7800
caatagttgg tggcctatga ccatgctgta taaggtaacc ataacattca ctaatggtca 7860
gccatctgct atatcagctc agaatgtgcc cacacagcag gtccctagac ctgggacagg 7920
aagctgctct gcaacaaata gatgtcccgg tttttgcttg aaaggagtgt atgctgatgc 7980
ctggttactg accaaccctt cgtctaccag tacatttgga tcagaagcaa ccttcactgg 8040
ttcttatctc aacgcagcaa ctcagcgtat caatccgacg atgtatatcg cgaacaacac 8100
acagatcata agctcacagc aatttggatc aagcggtcaa gaagcagcat atggccacac 8160
aacttgtttt agggacacag gctctgttat ggtatactgt atctatatta ttgaattgtc 8220
ctcatctctc ttaggacaat ttcagattgt cccatttatc cgtcaggtga cactatccta 8280
aaggcagaag catccaggtc tgacccagcc aatcaaagca ttataccaga ccatggaatg 8340
cataccaaac attattgaca ctaatgacac acaaaattgg ttttaagaaa aaccaagaga 8400
acaataggcc agaatggctg ggtctcggga gatattactc cctgaagtcc atctcaattc 8460
accaattgta aagcataagc tatactatta cattctactt ggaaacctcc caaatgagat 8520
cgacattgac gatttaggtc cattacataa tcaaaattgg aatcaaatag cacatgaaga 8580
gtctaactta gcccaacgct tggtaaatgt aagaaatttt ctaattaccc acatctctga 8640
tcttagaaag ggccattggc aagagtatgt caatgtaata ctgtggccgc gaattcttcc 8700
cttgatcccg gattttaaaa tcaatgacca attgcctcta ctcaaaaatt gggacaagtt 8760
agttaaagaa tcatgttcag taatcaatgc gggtacttcc cagtgcattc agaatctcag 8820
ctatggactg acaggtcgtg ggaacctctt tacacgatca cgtgaactct ctggtgaccg 8880
cagggatatt gatcttaaga cggttgtggc agcatggcat gactcagact ggaaaagaat 8940
aagtgatttt tggattatga tcaaattcca gatgagacaa ttaattgtta ggcaaacaga 9000
tcataatgat cctgatttaa tcacgtatat cgaaaataga gaaggcataa tcatcataac 9060
ccctgaactg gtagcattat ttaacactga gaatcataca ctaacataca tgacctttga 9120
aattgtactg atggtttcag atatgtacga aggtcgtcac aacattttat cactatgcac 9180
agttagcact tacctgaatc ctctgaagaa aagaataaaa tatttattga gccttgtaga 9240
taacttagct tttcagatag gtgatgctgt atataacata attgctttgc tagaatcctt 9300
tgtatatgca cagttgcaaa tgtcagatcc catcccagaa ctcagaggac aattccatgc 9360
attcgtatgt tctgagattc ttgatgcact aaggggaact aatagtttca cccaggatga 9420
atcaagaact gtgacaacca atttgatatc cccattccaa gatctgaccc cagatcttac 9480
ggctgaattg ctctgtataa tgaggctttg gggacacccc atgctcaccg ccagtcaagc 9540
tgcgggaaag gtacgcgagt ccatgtgtgc tggaaaagta ttagactttc ccaccattat 9600
gaaaacacta gcctttttcc atactattct gatcaatgga tacaggagga agcatcatgg 9660
agtatggcca cccttaaact taccgggtaa tgcttcaaag ggtctcacgg aacttatgaa 9720
tgacaatact gagataagct atgaattcac acttaagcat tggaaggaaa tctctcttat 9780
aaaattcaag aaatgttttg atgcagacgc aggtgaggaa ctcagtatat ttatgaaaga 9840
taaagcaatt agtgccccaa aacaagattg gatgagtgtg tttagaagaa gcctaatcaa 9900
acagcgccat cagcatcatc aggtccccct accaaatcca ttcaatcgac ggctattgct 9960
aaactttctc ggagatgaca aattcgaccc gaatgtggag ctacagtatg taacatcagg 10020
tgagtatcta catgatgaca cgttttgtgc atcatattca ctaaaagaga aggaaattaa 10080
acctgatggt cgaatttttg caaagttgac taagagaatg agatcatgtc aagttatagc 10140
agaatctctt ttagcgaacc atgctgggaa gttaatgaaa gagaatggtg ttgtgatgaa 10200
tcagctatca ttaacaaaat cactattaac aatgagtcag attggaataa tatccgagaa 10260
agctagaaaa tcgactcgag ataacataaa tcaacctggt ttccagaata tccagagaaa 10320
taaatcacat cactccaagc aagtcaatca gcgagatcca agtgatgact ttgaattggc 10380
agcatctttt ttaactactg atctcaaaaa atattgttta caatggaggt accagacaat 10440
tatcccattt gctcaatcat taaacagaat gtatggttat cctcatctct ttgagtggat 10500
tcacttacgg ctaatgcgta gtacacttta cgtgggggat cccttcaacc caccagcaga 10560
taccagtcaa tttgatctag ataaagtaat taatggagat atcttcattg tatcacccag 10620
aggtggaatt gaagggctat gtcaaaaggc ttggacaatg atatctatct ctgtgataat 10680
tctatctgcc acagagtctg gcacacgagt aatgagtatg gtgcagggag ataatcaagc 10740
aattgctgtc accacacgag taccaaggag cctgccgact cttgagaaaa agactattgc 10800
ttttagatct tgtaatctat tctttgagag gttaaaatgt aataattttg gattaggtca 10860
ccatttgaaa gaacaagaga ctatcattag ttctcacttc tttgtttata gcaagagaat 10920
attctatcag gggaggattc taacgcaagc cttaaaaaat gctagtaagc tctgcttgac 10980
agctgatgtc ctaggagaat gtacccaatc atcatgttct aatcttgcaa ctactgtcat 11040
gaggttaact gagaatggtg ttgaaaaaga tatctgtttc tacttgaata tctatatgac 11100
catcaaacag ctctcctatg atatcatctt ccctcaagtg tcaattcctg gagatcagat 11160
cacattagaa tacataaata atccacacct ggtatcacga ttggctcttc tgccatccca 11220
gctaggaggt ctaaactacc tgtcatgcag taggctgttc aatcgaaaca taggagaccc 11280
ggtggtttcc gcagttgcag atcttaagag attaattaaa tcaggatgta tggattactg 11340
gatcctttat aacttattag ggagaaaacc gggaaacggc tcatgggcta ctttagcagc 11400
tgacccgtac tcaatcaata tagagtatca atacccccca actacagctc ttaagaggca 11460
cacccaacaa gctctgatgg aactcagtac gaatccaatg ttacgtggca tattctctga 11520
caatgcacag gcagaagaaa ataatcttgc tagatttctc ctggataggg aggtgatctt 11580
tccgcgtgta gctcacatca tcattgagca aaccagtgtc gggaggagaa aacagattca 11640
aggatatttg gattcaacta gatcaataat gagtaaatca ctagaaatta agcccttgtc 11700
caataggaag cttaatgaaa tactggatta caacatcaat tacctagctt acaatttggc 11760
attactcaag aatgctattg aacctccgac ttatttgaaa gcaatgactc ttgaaacatg 11820
tagcatcgac attgcaagga gcctccggaa gctctcctgg gccccactct tgggtgggag 11880
aaatcttgaa gggttagaga cgccagatcc cattgaaatt actgcaggag cattaattgt 11940
tggatcgggc tactgtgaac agtgtgctgc aggagacaat cgattcacat ggtttttctt 12000
gccatctggt atcgagatag gaggggatcc ccgtgataat cctcctatcc gtgtaccgta 12060
cattggctcc aggactgatg agaggagggt agcctcaatg gcatacatca ggggtgcctc 12120
gagtagccta aaagcagttc ttagactggc gggagtgtac atctgggcat tcggagatac 12180
tctggagaat tggatagatg cactggattt gtctcacact agagttaaca tcacacttga 12240
acagctgcaa tccctcaccc cacttccaac ctctgccaat ctaacccatc ggttggatga 12300
tggcacaact accctaaagt ttactcctgc gagctcttac accttttcaa gtttcactca 12360
tatatcaaat gatgagcaat acctgacaat taatgacaaa actgcagatt caaatataat 12420
ctaccaacag ttaatgatca ctggactcgg aattttagaa acatggaata atcccccaat 12480
caatagaaca ttcgaagaat ctaccctaca tttgcacact ggtgcatcat gttgtgtccg 12540
acctgtggac tcctgcatca tctcagaagc attaacagtc aagccacata ttacagtacc 12600
gtacagcaat aaatttgtat ttgatgaaga cccgctatct gaatatgaga ctgcaaaact 12660
ggaatcgtta tcatttcaag cccaattagg caacattgat gctgtagata tgacaggtaa 12720
attaacatta ttgtcccaat tcactgcaag gcagattatt aatgcaatca ctggactcga 12780
tgagtctgtc tctcttacta atgatgccat tgttgcatca gactatgtct ccaattggat 12840
tagtgaatgc atgtatacca aattagatga attatttatg tattgtgggt gggaactact 12900
attggaacta tcctatcaaa tgtattatct gagggtagtt gggtggagta atatagtgga 12960
ttattcttac atgatcttga gaagaatccc gggtgcagca ttaaacaatc tggcatctac 13020
attaagtcat ccaaaacttt tccgacgagc tatcaaccta gatatagttg cccccttaaa 13080
tgctcctcat tttgcatctc tggactacat caagatgagt gtggatgcaa tactctgggg 13140
ctgtaaaaga gtcatcaatg tgatctccaa tggaggggac ttagaattag ttgtgacatc 13200
tgaagatagc cttattctca gtgaccgatc catgaatctc attgcaagga aattaacttt 13260
attatcactg attcaccata atggtttgga actaccaaag attaaggggt tctctcctga 13320
tgagaagtgt ttcgctttga cagaattttt gaggaaagtg gtgaactcag ggttgagttc 13380
aatagagaac ctatcaaatt ttatgtacaa tgtggagaac ccacggcttg cagcattcgc 13440
cagcaacaat tactacctga ccagaaaatt attgaattca atacgagata ctgagtcggg 13500
tcaagtagca gtcacctcat attatgaatc attagaatat attgatagtc ttaagctaac 13560
cccacatgtg cctggtacct catgcattga ggatgatagt ctatgtacaa atgattacat 13620
aatctggatc atagagtcta atgcaaactt ggagaagtat ccaattccaa atagccctga 13680
ggatgattcc aatttccata actttaagtt gaatgctcca tcgcaccata ccttacgccc 13740
attagggttg tcatcaactg cttggtataa gggtataagc tgttgcaggt accttgagcg 13800
attaaagcta ccacaaggtg atcatttata tattgcagaa ggtagtggtg ccagtatgac 13860
aatcatagaa tacctattcc caggaagaaa gatatattac aattctttat ttagtagtgg 13920
tgacaatccc ccacaaagaa attatgcacc aatgcctact cagttcattg agagtgtccc 13980
atacaagctc tggcaagcac acacagatca atatcccgag atttttgagg acttcatccc 14040
tctatggaac ggaaatgccg ccatgactga cataggaatg acagcttgtg tagaattcat 14100
catcaatcga gtcggcccaa ggacttgcag tttagtacat gtagatttgg aatcaagtgc 14160
aagcttaaat caacaatgcc tgtcaaagcc gataattaat gctatcatca ctgctacaac 14220
tgttttgtgc cctcatgggg tgcttattct gaaatatagt tggttgccat ttactagatt 14280
tagtactttg atcactttct tatggtgcta ctttgagaga atcactgttc ttaggagcac 14340
atattctggt ccagctaatc atgaggttta tttaatttgt atccttgcca acaactttgc 14400
attccagact gtctcgcagg caacaggaat ggcgatgact ttaaccgatc aagggtttac 14460
tttgatatca cctgaaagaa taaatcagta ttgggatggt cacttgaagc aagaacgtat 14520
cgtagcagaa gcaattgata aggtggttct aggagaagat gctctattca attcgagtga 14580
taatgaatta attctcaaat gtggagggac accaaatgca cggaatctta tcgatatcga 14640
gccagtcgca actttcatag aatttgaaca actgatctgc acaatgttaa caacccactt 14700
gaaggaaata attgatataa caaggtctgg aacccaggat tatgaaagtt tattactcac 14760
tccttacaat ttaggtcttc ttggtaaaat cagtacgata gtgagattat taacagaaag 14820
gattctaaat catactatca ggaattggtt gatcctccca ccttcgctcc ggatgatcgt 14880
gaagcaggac ttggaattcg gcatattcag gattacttcc atcctcaatt ctgatcggtt 14940
cctgaagctt tctccaaata ggaaatactt gattacacaa ttaactgcag gctacattag 15000
gaaattgatt gagggggatt gtaatatcga tctaaccagg cctatccaaa aacaaatctg 15060
gaaagcatta ggttgtgtag tctattgtca cgatccagta gatcaaaggg aatcaacaga 15120
gtttattgat ataaatatta atgaagaaat agacctcggg atcgatggcg aggaaatcta 15180
aatatatcaa gaatcagaat tagtttaaga aaaaagaagt ggattaatct tggttttccc 15240
cttggt 15246
<210> 7
<211> 28
<212> DNA
<213> 人工序列
<400> 7
aggtcgatgt tgtgcaagtg catgcagc 28
<210> 8
<211> 37
<212> DNA
<213> 人工序列
<400> 8
ggtggtttaa acagatttga gctttccgag acggtag 37
<210> 9
<211> 40
<212> DNA
<213> 人工序列
<400> 9
aaatctgttt aaaccacctg ctataggcta tccactgcat 40
<210> 10
<211> 23
<212> DNA
<213> 人工序列
<400> 10
agtgtcagct tgcgaccctc agc 23
<210> 11
<211> 65
<212> DNA
<213> 人工序列
<400> 11
gtctcggaaa gctcaaatcg tttaaacgcc accatgtttg tttttcttgt tttattgcca 60
ctagt 65
<210> 12
<211> 30
<212> DNA
<213> 人工序列
<400> 12
tgatagattc ctttctctac agtgaaggat 30
<210> 13
<211> 30
<212> DNA
<213> 人工序列
<400> 13
atccttcact gtagagaaag gaatctatca 30
<210> 14
<211> 36
<212> DNA
<213> 人工序列
<400> 14
agagtaagca actgaattct ctgcaccaag tgacat 36
<210> 15
<211> 36
<212> DNA
<213> 人工序列
<400> 15
atgtcacttg gtgcagagaa ttcagttgct tactct 36
<210> 16
<211> 36
<212> DNA
<213> 人工序列
<400> 16
agcagttgtg aagttcttct cttgtgcagg gacata 36
<210> 17
<211> 36
<212> DNA
<213> 人工序列
<400> 17
tatgtccctg cacaagagaa gaacttcaca actgct 36
<210> 18
<211> 60
<212> DNA
<213> 人工序列
<400> 18
ggatagccta tagcaggtgt ttaaacttat gtgtaatgta atttgactcc tttgagcact 60
<210> 19
<211> 46
<212> DNA
<213> 人工序列
<400> 19
cagactaatt ctcctgcaag tgtagctagt caatccatca ttgcct 46
<210> 20
<211> 44
<212> DNA
<213> 人工序列
<400> 20
tgactagcta cacttgcagg agaattagtc tgagtctgat aact 44
<210> 21
<211> 26
<212> DNA
<213> 人工序列
<400> 21
caactcttgg aacaagataa gacagt 26
<210> 22
<211> 24
<212> DNA
<213> 人工序列
<400> 22
catcttctgc aaccattgta gtgt 24

Claims (10)

1.一种表达冠状病毒Spike蛋白的重组副流感病毒5型载体,其特征在于,所述重组副流感病毒5型载体包含一种副流感病毒5型基因组,所述基因组包含冠状病毒Spike蛋白突变体的编码序列;所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列,且冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点。
2.根据权利要求1所述的表达冠状病毒Spike蛋白的重组副流感病毒5型载体,其特征在于,所述冠状病毒为2019-nCoV。
3.根据权利要求1或2所述的表达冠状病毒Spike蛋白的重组副流感病毒5型载体,其特征在于,所述副流感病毒5型基因组为:用序列甲替换一种副流感病毒5型基因组的小疏水蛋白基因序列,所得;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示核苷酸序列第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位核苷酸由A突变为G,且第2044位至2055位替换为GCA,得到的DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点,所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点,所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列。
4.一种在细胞中表达冠状病毒Spike蛋白的方法,其特征在于,该方法包括使该细胞与如权利要求1至3中任一项所述的表达冠状病毒Spike蛋白的重组副流感病毒5型载体相接触。
5.一种表达冠状病毒Spike蛋白的重组副流感病毒5型载体的制备方法,其特征在于,包括如下步骤:
1)将副流感病毒5型全基因组反转录得到的cDNA插入克隆载体中,得到重组质粒pPIV5;
2)用序列甲替换步骤1)中重组质粒pPIV5中副流感病毒5型的小疏水蛋白基因核苷酸序列;
所述序列甲为如下1)或2)或3):
A)SEQ ID NO:1所示核苷酸序列第927位核苷酸由A突变为G、第3216位核苷酸由A突变为G、第2106位核苷酸由A突变为G,且第2044位至2055位替换为GCA,得到的DNA分子;
B)在严格条件下与A)限定的DNA分子杂交且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点,所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列;
C)与A)或B)限定的DNA序列具有99%以上、95%以上、90%以上、85%以上或者80%以上同一性且编码所述冠状病毒Spike蛋白突变体的DNA序列,冠状病毒Spike蛋白突变体的氨基酸序列上不含有Furin蛋白酶裂解位点,所述冠状病毒Spike蛋白突变体的编码序列不含有副黏病毒转录终止序列。
6.根据权利要求5所述的方法,其特征在于,步骤1)中所述克隆载体为带有T7 RNA聚合酶启动子序列、带有丁肝核酶序列、T7 RNA聚合酶转录终止序列的克隆载体。
7.一种新型冠状病毒(2019-nCoV)疫苗的制备方法,其特征在于,所述疫苗的制备方法包括如下步骤:将权利要求1-3任一所述表达冠状病毒Spike蛋白的重组副流感病毒5型载体、表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L共转染宿主细胞;所述表达辅助蛋白的辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L是将副流感病毒5型的NP、P和L蛋白的编码基因分别插入哺乳动物表达载体中,得到辅助重组质粒—NP、辅助重组质粒—P和辅助重组质粒—L。
8.根据权利要求7所述的制备方法,其特征在于,所述宿主细胞为BSR-T7细胞,MDBK细胞,Vero细胞或BHK-21细胞。
9.权利要求7或8所述方法制备得到的疫苗。
10.权利要求1-3任一所述重组副流感病毒5型载体或权利要求5或6所述方法制备的重组副流感病毒5型载体在如下任一一种中的应用:
(1)制备提高动物体内针对冠状病毒2019-nCoV Spike蛋白抗体水平的产品中的应用;
(2)制备预防或辅助预防冠状病毒2019-nCoV引起的疾病产品中的应用。
CN202110362266.0A 2021-04-02 2021-04-02 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用 Active CN113073116B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110362266.0A CN113073116B (zh) 2021-04-02 2021-04-02 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110362266.0A CN113073116B (zh) 2021-04-02 2021-04-02 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用

Publications (2)

Publication Number Publication Date
CN113073116A true CN113073116A (zh) 2021-07-06
CN113073116B CN113073116B (zh) 2022-11-11

Family

ID=76615038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110362266.0A Active CN113073116B (zh) 2021-04-02 2021-04-02 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用

Country Status (1)

Country Link
CN (1) CN113073116B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832168A (zh) * 2021-08-15 2021-12-24 北京科兴中维生物技术有限公司 mRNA疫苗及其制备方法和应用
CN114560915A (zh) * 2021-12-27 2022-05-31 中国食品药品检定研究院 一种改造的高滴度SARS-CoV-2假病毒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176510A1 (en) * 2015-04-28 2016-11-03 University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
US20180339038A1 (en) * 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
CN112375784A (zh) * 2021-01-07 2021-02-19 北京百普赛斯生物科技股份有限公司 制备重组新型冠状病毒Spike蛋白的方法
WO2022061264A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176510A1 (en) * 2015-04-28 2016-11-03 University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
US20180339038A1 (en) * 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
WO2022061264A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine
CN112375784A (zh) * 2021-01-07 2021-02-19 北京百普赛斯生物科技股份有限公司 制备重组新型冠状病毒Spike蛋白的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUN LI ET AL: "Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection", 《MBIO》 *
闫微等: "人3型副流感病毒疫苗的研究进展", 《生命科学》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832168A (zh) * 2021-08-15 2021-12-24 北京科兴中维生物技术有限公司 mRNA疫苗及其制备方法和应用
CN114560915A (zh) * 2021-12-27 2022-05-31 中国食品药品检定研究院 一种改造的高滴度SARS-CoV-2假病毒
CN114560915B (zh) * 2021-12-27 2024-01-09 中国食品药品检定研究院 一种改造的高滴度SARS-CoV-2假病毒

Also Published As

Publication number Publication date
CN113073116B (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
Krishnamurthy et al. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation
KR0179994B1 (ko) 칠면조의 재조합 포진바이러스 및 이로부터 유도된 생존상태의 벡터 백신
Kato et al. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis
Kato et al. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis
CN113073116B (zh) 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
WO2021051906A1 (zh) 一种针对ii类vii型流行ndv株dhn3的感染性重组克隆方法
CN112011521A (zh) 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用
EP3592779A1 (en) A composite multi-epitope expression cassette, a recombinant virus composed thereof and application thereof
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN109321535A (zh) 一种热稳定的新城疫病毒弱毒疫苗候选株
CN104471064A (zh) 新型副粘病毒及其用途
CN113913461A (zh) 牛病毒性腹泻e0-e2基因重组腺病毒疫苗构建方法
CN112111503B (zh) 同时预防禽流感h5和h9亚型的腺病毒载体二价苗及其制备方法
WO2021051907A1 (zh) 一种全基因组表达载体pBR322-DHN3的制备方法
KR102154796B1 (ko) 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
KR102154794B1 (ko) 조류 인플루엔자 바이러스 h9n2의 표면항원을 발현하는 뉴캣슬병 바이러스 발현 시스템 및 이를 이용한 조류 백신
US20210275662A1 (en) Method for rescuing and producing a virus in avian cells
CN114410593B (zh) 一种以麻疹病毒为载体的重组新型冠状病毒疫苗的大规模生产工艺
CN112111467B (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
CN112029735B (zh) 一种口蹄疫病毒非结构蛋白3b优势表位缺失标记毒株及其制备方法和应用
CN109295095A (zh) 一种热稳定的基因viii型新城疫弱毒株外源基因表达载体
CN106119207B (zh) 一种基于反向遗传技术构建的IBV Vero细胞适应株
CN113005149A (zh) 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
WO2022163902A1 (ko) 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant